Updated read me file and evaluation plan text

Evaluation/Input/Content/References.md

@@ -29,6 +29,8 @@ of substrates, inhibitors and inducers. https://www.fda.gov/drugs/drug-interacti
 
 **Gusler 2001** Gusler G, Gorsline J, Levy G, et al (2001) Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 41:655–661. https://doi.org/10.1177/00912700122010546
 
+**Hanke 2020** Hanke N, Türk D, Selzer D, et al (2020) A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. Clin Pharmacokinet. 59:1419-1431. doi: 10.1007/s40262-020-00896-w. 
+
 **Hibma 2016** Hibma JE, Zur AA, Castro RA, et al (2016) The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet 55:711–721. https://doi.org/10.1007/s40262-015-0346-3
 
 **Jang 2016** Jang K, Chung H, Yoon J-S, et al (2016) Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects. J Clin Pharmacol 56:1104–1110. https://doi.org/10.1002/jcph.699

Evaluation/Input/Content/Section1_Introduction.md

@@ -1,5 +1,7 @@
 The presented model building and evaluation report evaluates the performance of a PBPK model for metformin in healthy adults.
 
+The herein presented model was developed and published by Hanke et al. [Hanke 2020](#5-references) and adjusted later on to PK-Sim V11 by re-optimizing OCT2.
+
 Metformin is widely used as first-line treatment of type 2 diabetes. It is a highly hydrophilic compound, positively
 charged at physiological pH and depends on active transport for its absorption, distribution and
 excretion. The absorption of metformin is saturable and reported to be restricted to the upper

README.md

@@ -7,7 +7,7 @@ Within this repository, we share a whole-body PBPK model of metformin that has b
 The PK-Sim project file contains simulation examples and the observed data of all clinical studies used for model development and evaluation. For further details, quantitative model evaluation, sensitivity analysis and extensive documentation please refer to [[1](#reference)].
 
 ### Version information
-PK-Sim Version 8.0.
+PK-Sim Version 11.
 
 ### License
 The model is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).